Evidence map›Paper›PMID 31680621›Full record

Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2020

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.

Jens Kuhle, Tatiana Plavina, Christian Barro, Giulio Disanto, Dipen Sangurdekar, Carol M Singh, Carl de Moor, Bob Engle, Bernd C Kieseier, Elizabeth Fisher and 3 more

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 61 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 3 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04550455 phase4unknown statusnot on this map

A Prospective Biomarker Study in Active Secondary Progressive Multiple Sclerosis (SPMS)Subjects Treated With Cladribine Tablets

TypeinterventionalSponsorKeith Edwards, M.D.Ran2020 to 2025Enrolled30ConditionsMultiple SclerosisArmsCladribine Tablets
NCT06629428 early_phase1recruitingnot on this mapstarted 2025, after this paper: background citation

Effects of Ublituximab on Unperturbed and Perturbed Ambulatory Functions in People With Relapsing Multiple Sclerosis

TypeinterventionalSponsorGeorgia State UniversityRan2025 to 2026Enrolled25ConditionsMultiple Sclerosis (MS) - Relapsing-remittingArmsUblituximab
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Jens KuhleNeurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Tatiana PlavinaBiogen, Cambridge, MA, USA.
Christian BarroNeurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
Giulio DisantoNeurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland/Neurocenter of Southern Switzerland, Ospedale Civico, Lugano, Switzerland.
Dipen SangurdekarBiogen, Cambridge, MA, USA.
Carol M SinghBiogen, Cambridge, MA, USA.
Carl de MoorBiogen, Cambridge, MA, USA.
Bob EngleBiogen, Cambridge, MA, USA.
Bernd C KieseierBiogen, Cambridge, MA, USA.
Elizabeth FisherBiogen, Cambridge, MA, USA.
Ludwig KapposNeurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0003-4175-5509
Richard A RudickBiogen, Cambridge, MA, USA.
Jaya GoyalBiogen, Cambridge, MA, USA.
Biogen (United States) · USUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurofilament light chain (NfL) is a promising marker of disease activity/treatment response in multiple sclerosis (MS), although its predictive value for long-term clinical outcomes remains unclear.

objectiveWe measured NfL from a phase 3 trial in relapsing-remitting MS and investigated its association with outcomes after 8 and 15 years.

methodsNfL concentrations were measured by single molecule array assay in cerebrospinal fluid (CSF) from MS patients (

resultsYear 2 CSF and Year 3 serum NfL were associated with brain parenchymal fraction (BPF) change over 8 years (

conclusionSerum and CSF NfL concentrations were associated with long-term clinical outcomes in MS patients and are promising biomarkers for disease severity stratification supporting treatment decisions.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingBiomarkersBrainHumansIntermediate FilamentsNeurofilament ProteinsBiomarkersNeurofilament ProteinsMRImultiple sclerosisNeurofilament

Identifiers

PMID31680621
PMCPMC7604552
OpenAlexW2983212738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.